Xortx welcomes new member to the board of directors

Calgary, alberta, april 08, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes abigail jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its board of directors.
XRTX Ratings Summary
XRTX Quant Ranking